ANN ARBOR, Michigan, April 30 (TNSjou) -- Michigan Medicine, the academic medical center of the University of Michigan, issued the following news release:

* * *

New dual-target drug may help overcome immunotherapy resistance in pancreatic cancer

The drug, SH-273, led to long-term tumor reduction in mouse models

*

Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%.